Ido P. Kema

Ido P. Kema

Auto-generated profile, based on publicly available information

Ido P. Kema

Department of Clinical Chemistry, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Clinical Biochemistry
Verified
Journal Article
Closed access
WJWilhelmina H.A. de Jong
Wilhelmina H.A. de Jong
GVGrietje Knol-de Vries
Grietje Knol-de Vries
IKIdo P. Kema
Ido P. Kema

7 February 2010 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
WJWilhelmina H. A. de Jong
Wilhelmina H. A. de Jong
MWMarianne H. L. I. Wilkens
Marianne H. L. I. Wilkens
GVGrietje Knol-de Vries
Grietje Knol-de Vries
IKIdo P. Kema
Ido P. Kema
Serotonin emerges as crucial neurotransmitter and hormone in a growing number of different physiologic processes. Besides extensive serotonin production previously noted in patients with metastatic carcinoid tumors, serotonin now is implicated in liver cell regeneration and bone formation. The aim was to develop a rapid, sensitive, and highly selective automated on-line solid-phase extraction method coupled to high-performance liquid chromatography–tandem mass spectrometry (XLC-MS/MS) to quantify low serotonin concentrations in matrices such as platelet-poor plasma and urine. Fifty microliters plasma or 2.5 μL urine equivalent were pre-purified by automated on-line solid-phase extraction, using weak cation exchange. Chromatography of serotonin and its deuterated internal standard was performed with hydrophilic interaction chromatography. Mass spectrometric detection was operated in multiple reaction monitoring mode using a quadrupole tandem mass spectrometer with positive electrospray ionization. Serotonin concentrations were determined in platelet-poor plasma of metastatic carcinoid patients (n = 23) and healthy controls (n = 22). Urinary reference intervals were set by analyzing 24-h urine collections of 120 healthy subjects. Total run-time was 6 min. Intra- and inter-assay analytical variation were 0.99). Quantification limits were 30 and 0.9 nmol/L in urine and plasma, respectively. Platelet-poor serotonin concentrations in metastatic carcinoid patients were significantly higher than in controls. The urinary reference interval was 10–78 μmol/mol creatinine. Serotonin analysis with sensitive and specific XLC-MS/MS overcomes limitations of conventional HPLC. This enables accurate quantification of serotonin for both routine diagnostic procedures and research in serotonin-related disorders.

1 June 2008 in Journal of Chromatography B
Verified
Journal Article
Closed access
WJWilhelmina H.A. de Jong
Wilhelmina H.A. de Jong
KGKendon S. Graham
Kendon S. Graham
GVGrietje Knol-de Vries
Grietje Knol-de Vries
IKIdo P. Kema
Ido P. Kema

1 February 2003
Verified
Journal Article
Closed access
WMWim G Meijer
Wim G Meijer
EVEveline Van Der Veer
Eveline Van Der Veer
PJPiet L Jager
Piet L Jager
EJErik J Van Der Jagt
Erik J Van Der Jagt
BPBert A Piers
Bert A Piers
PWPax H B Willemse
Pax H B Willemse

1 June 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
WJWilhelmina H. A. de Jong
Wilhelmina H. A. de Jong
WPWendy J. Post
Wendy J. Post
MKMichiel N. Kerstens
Michiel N. Kerstens
GVGrietje Knol-de Vries
Grietje Knol-de Vries
IKIdo P. Kema
Ido P. Kema
The biochemical diagnosis of pheochromocytoma depends on the demonstration of elevated levels of catecholamines (i.e. epinephrine, norepinephrine, and dopamine) and their metabolites. The aim of the study was to determine the preanalytical influence of a catecholamine-rich diet on urinary free and deconjugated catecholamines in healthy volunteers with a highly specific and sensitive analytical technique. We conducted a crossover study involving 27 healthy adults in a specialist medical center. Subjects consumed catecholamine-rich nuts and fruits at fixed times on one day (about 35 micromol dopamine and 1 micromol norepinephrine) and catecholamine-poor products on another day. Urine samples were collected at timed intervals before, during, and after experimental and control interventions. We performed automated online sample preparation coupled to isotope-dilution mass spectrometry measurements of urinary concentrations of free and deconjugated catecholamines. The catecholamine-rich diet had substantial effects on urinary excretions of deconjugated dopamine (up to 20-fold increases) and norepinephrine (up to 10-fold). Dietary catecholamines had less but significant effects on urinary excretion of free dopamine and norepinephrine (up to 1.5-fold increases). Outputs of urinary free and deconjugated epinephrine remained unaffected. Urinary excretion of deconjugated norepinephrine and dopamine is strongly affected by consumption of catecholamine-rich food products, thereby increasing the likelihood of a false-positive test result during hormonal evaluation for pheochromocytoma. Measurement of deconjugated catecholamines should therefore preferably be avoided, in favor of measurement of urinary free catecholamines. In case of demonstrating increased urinary excretion of deconjugated norepinephrine and dopamine, repeated measurements are warranted with dietary restrictions prior to sample collection.

11 May 2011 in Cancers
Verified
Journal Article
Open access
PDF file
IGIrene Grossmann
Irene Grossmann
CVCharlotte Verberne
Charlotte Verberne
GBGeertruida de Bock
Geertruida de Bock
KHKlaas Havenga
Klaas Havenga
IKIdo Kema
Ido Kema
TWTheo Wiggers
Theo Wiggers
Following curative treatment for colorectal cancer (CRC), 30% to 50% of patients will develop recurrent disease. For CRC there are several lines of evidence supporting the hypothesis that early detection of metachronous disease offers a second opportunity for cure. This paper revisits the potential role of serum carcinoembryonic antigen (CEA) in follow-up. A comprehensive review of the literature (1978–2008) demonstrates that the initial promise of serum CEA as an effective surveillance tool has been tarnished through perpetuation of poorly designed studies. Specific limitations included: testing CEA as only an ‘add-on’ diagnostic tool; lack of standardization of threshold values; use of static thresholds; too low measurement frequency. Major changes in localizing imaging techniques and treatment of metastatic CRC further cause a decrease of clinical applicability of past trial outcomes. In 1982, Staab hypothesized that the optimal benefit of serum CEA as a surveillance tool is through high-frequency triage using a dynamic threshold (HiDT). Evidence supporting this hypothesis was found in the biochemical characteristics of serum CEA and retrospective studies showing the superior predictive value of a dynamic threshold. A multi-centred randomized phase III study optimizing the usage of HiDT against resectability of recurrent disease is commencing recruitment in the Netherlands.